
|Videos|May 5, 2014
The Impact of FLT3 Inhibitors for the Treatment of AML
Author(s)Meir Wetzler, MD
Meir Wetzler, MD, from Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.
Advertisement
Clinical Pearls
Meir Wetzler, MD, chief, Leukemia Section, Department of Medicine, Professor of Medicine, Department of Medicine, Roswell Park Cancer Institute, discusses the potential impact of FLT3 inhibitors for the treatment of patients with acute myeloid leukemia.
- In CML, initially only imatinib was available in the frontline, but now nilotinib and dasatinib are approved.
- FLT3 inhibitors did not show significant efficacy in the relapsed/refractory setting of AML, so they were evaluated in the frontline.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors
2
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
3
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
4
COSMIC-313 Trial: KIM-1 Associated With Clinical Outcomes in Advanced RCC
5









































